Literature DB >> 18431286

Sepsis: time to reconsider the concept.

Jean Carlet1, Jonathan Cohen, Thierry Calandra, Steven M Opal, Henry Masur.   

Abstract

OBJECTIVE: To discuss the difficulty in using the concept of sepsis for clinical trials and propose new ways for designing future trials for severe infections.
DESIGN: Short position statement. METHODS AND MAIN RESEARCH: Using a thorough evaluation of the recent literature in the field of severe sepsis and septic shock, the authors challenge the concept of sepsis as used in the past two decades and propose new ideas for designing future trials in this setting. The two main proposals are first to use a systematic assessment of the targeted inflammatory mediators when the study intends to counteract or replace those mediators (e.g., anti-tumor necrosis factor-alpha, activated protein C) and, second, to select more homogeneous populations, coming back to "precise infectious diseases," such as severe community-acquired pneumonia, severe peritonitis, or meningitis.
CONCLUSIONS: The concept of sepsis has been useful to help clinicians to suspect and detect severe infections. Due to a considerable heterogeneity in the patients and type of infections included in the trials performed in the last two decades, it has not been useful in demonstrating the efficacy of new compounds. The authors propose a dramatic change in the design of future trials dealing with severe infections.

Entities:  

Mesh:

Year:  2008        PMID: 18431286     DOI: 10.1097/CCM.0B013E318165B886

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  34 in total

1.  Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure.

Authors:  Joerg C Schefold
Journal:  Intensive Care Med       Date:  2010-07-23       Impact factor: 17.440

2.  [Sepsis therapy -- how effective are the therapy strategies?].

Authors:  E Hanisch
Journal:  Chirurg       Date:  2008-09       Impact factor: 0.955

3.  Sepsis in the severely immunocompromised patient.

Authors:  Andre C Kalil; Steven M Opal
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

4.  Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients.

Authors:  Caroline Guignant; Nicolas Voirin; Fabienne Venet; Françoise Poitevin; Christophe Malcus; Julien Bohé; Alain Lepape; Guillaume Monneret
Journal:  Intensive Care Med       Date:  2009-08-07       Impact factor: 17.440

5.  PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes.

Authors:  Qian Liu; Yi Lv; Min Zhao; Yiduo Jin; Jiangyang Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

6.  Severity of ICU-acquired pneumonia according to infectious microorganisms.

Authors:  Pierre Damas; Nathalie Layios; Laurence Seidel; Monique Nys; Pierrette Melin; Didier Ledoux
Journal:  Intensive Care Med       Date:  2011-05-26       Impact factor: 17.440

Review 7.  Hsp70 and cardiac surgery: molecular chaperone and inflammatory regulator with compartmentalized effects.

Authors:  Petrus R de Jong; Alvin W L Schadenberg; Nicolaas J G Jansen; Berent J Prakken
Journal:  Cell Stress Chaperones       Date:  2008-07-31       Impact factor: 3.667

Review 8.  Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.

Authors:  Derek S Wheeler; Basilia Zingarelli; William J Wheeler; Hector R Wong
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2009-06

Review 9.  Year in review 2008: Critical Care--sepsis.

Authors:  Steven M Opal; Steven P LaRosa
Journal:  Crit Care       Date:  2009-10-21       Impact factor: 9.097

10.  Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis.

Authors:  Holger Poehlmann; Joerg C Schefold; Heidrun Zuckermann-Becker; Hans-Dieter Volk; Christian Meisel
Journal:  Crit Care       Date:  2009-07-15       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.